3NICKOLOOF B J.The immunologic and genetic basis of psoriasis[J].Arch Dermatol,1999,135:1104-1110.
4KRUEGER J G.The immunologic basis for the treatment of psoriasis with new biologic agent[J].J Am Acad Dermatol,2002,46:1-23.
二级参考文献3
1Katz HI,Waalen J,Leach EE.Acitretin in psoriasis: an overview of adverse effects[J].J Am Acad Dermatol,1999,41(3 Pt 2):S7-12.
2Orfanos CE.Treatment of psoriasis with retinoids: present status [J].Cutis,1999,64(5): 347-353.
3Saurat JH.Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment [J].J Am Acad Dermatol,1999,41(3 Pt 2): S2-6.
2Marks R, Barton SP, Shuttleworth D, et al. Assessment of disease progress in psoriasis. Arch Dennatol 1989; 125(2) :235 - 240.
3Picker LJ, Kisnimoto TK, Smith CW. ELAM- 1 is an adhesion molecule for skin - homing T cells. Nature 1991 ;349:796.
4Onuma S. Immunohistochemical stukies of infiltrating cells in early and chronic of psoriasis. Dermatol 1994;21:223.
5Krane JF, Murphy DP, Gottheb AB, et al. Increased dermal expression of platelet - derived growth factor receptors in growth - activated skin wounds and psoriasis. J Invest Dermatol 1991 ;96:983- 986.
6Ansel JC, Tiesman JP, Olerud JE, ct al. Human keratinocytes are a major source of cutaneous platelet - derived growth factor. J Clin Invest 1993;92:671 - 678.
7Bos JD, Rie MA, Teunissen MB, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005;152:1098- 1107.
